| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | -0.1 | 0.008 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.15 | 0.008 |
| mRNA | S-Trityl-L-cysteine | GDSC1000 | pan-cancer | AAC | -0.14 | 0.008 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.089 | 0.009 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | -0.085 | 0.009 |
| mRNA | CI-976 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.009 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | -0.1 | 0.01 |
| mRNA | KHS101 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.01 |
| mRNA | NG-25 | GDSC1000 | pan-cancer | AAC | -0.079 | 0.01 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.087 | 0.01 |